Q-omics provides the consensus-scored CCDC183 profile across patient tissues and cancer cell-line models. CCDC183 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CCDC183 is differentially expressed in 14, with the highest sampling consensus in LIHC. Additionally, CCDC183 RNA expression shows 19,334 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where CCDC183 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC183 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC183 survival associations across molecular data types. CCDC183 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC183 RNA expression–survival associations across cancer types. High CCDC183 expression shows unfavorable associations in ACC, LIHC, KIRC, PRAD and UVM, but favorable associations in MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CCDC183 RNA expression.
This table summarizes CCDC183 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC183. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC183 shows lower tumor expression in THCA and LUAD and higher tumor expression in LIHC, COAD, KIRC and CHOL. The LIHC box plot shows higher CCDC183 RNA expression in tumor versus normal tissue (log2 FC = +0.584, t-test p < 0.001).
This table shows molecular features associated with CCDC183 in patient tissues and cancer cell lines. In patient samples, CCDC183 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC183 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BREAST.
